Principal Financial Group Inc. increased its holdings in HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 1.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 266,841 shares of the company's stock after purchasing an additional 3,873 shares during the quarter. Principal Financial Group Inc. owned approximately 0.31% of HealthEquity worth $23,581,000 at the end of the most recent reporting period.
Several other institutional investors also recently modified their holdings of the business. Ameritas Investment Partners Inc. grew its stake in shares of HealthEquity by 0.3% in the fourth quarter. Ameritas Investment Partners Inc. now owns 33,856 shares of the company's stock worth $3,248,000 after purchasing an additional 88 shares during the last quarter. Smartleaf Asset Management LLC grew its stake in shares of HealthEquity by 34.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 384 shares of the company's stock worth $37,000 after purchasing an additional 98 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its stake in shares of HealthEquity by 0.6% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 19,286 shares of the company's stock worth $1,850,000 after purchasing an additional 106 shares during the last quarter. Hancock Whitney Corp grew its stake in shares of HealthEquity by 1.0% in the fourth quarter. Hancock Whitney Corp now owns 13,326 shares of the company's stock worth $1,279,000 after purchasing an additional 133 shares during the last quarter. Finally, Level Four Advisory Services LLC grew its stake in shares of HealthEquity by 5.3% in the fourth quarter. Level Four Advisory Services LLC now owns 2,736 shares of the company's stock worth $263,000 after purchasing an additional 138 shares during the last quarter. Institutional investors own 99.55% of the company's stock.
HealthEquity Stock Down 2.8%
Shares of NASDAQ HQY traded down $2.79 during trading on Thursday, hitting $97.19. 913,190 shares of the company traded hands, compared to its average volume of 869,222. The business's fifty day moving average is $100.90 and its 200 day moving average is $98.42. HealthEquity, Inc. has a fifty-two week low of $65.01 and a fifty-two week high of $116.65. The firm has a market capitalization of $8.40 billion, a price-to-earnings ratio of 70.94, a P/E/G ratio of 1.54 and a beta of 0.49. The company has a debt-to-equity ratio of 0.50, a quick ratio of 4.06 and a current ratio of 4.06.
HealthEquity (NASDAQ:HQY - Get Free Report) last posted its earnings results on Tuesday, June 3rd. The company reported $0.97 earnings per share for the quarter, topping analysts' consensus estimates of $0.81 by $0.16. The company had revenue of $330.80 million for the quarter, compared to analyst estimates of $322.25 million. HealthEquity had a net margin of 9.80% and a return on equity of 11.01%. During the same quarter in the prior year, the business posted $0.80 EPS. Equities research analysts predict that HealthEquity, Inc. will post 2.32 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
HQY has been the topic of a number of research analyst reports. Bank of America upped their price target on shares of HealthEquity from $110.00 to $125.00 and gave the company a "buy" rating in a research report on Wednesday, June 4th. Wall Street Zen raised shares of HealthEquity from a "hold" rating to a "buy" rating in a research report on Friday, June 6th. Royal Bank Of Canada upped their price target on shares of HealthEquity from $112.00 to $117.00 and gave the company an "outperform" rating in a research report on Wednesday, June 4th. Raymond James Financial reaffirmed a "strong-buy" rating and set a $120.00 price target (up previously from $115.00) on shares of HealthEquity in a research report on Tuesday. Finally, JMP Securities upped their price target on shares of HealthEquity from $110.00 to $117.00 and gave the company a "market outperform" rating in a research report on Wednesday, June 4th. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $118.55.
Check Out Our Latest Stock Report on HQY
Insider Transactions at HealthEquity
In other HealthEquity news, EVP Elimelech Rosner sold 58,000 shares of the firm's stock in a transaction on Friday, June 6th. The shares were sold at an average price of $112.56, for a total value of $6,528,480.00. Following the completion of the transaction, the executive vice president directly owned 75,689 shares of the company's stock, valued at $8,519,553.84. This trade represents a 43.38% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jon Kessler sold 97,767 shares of the firm's stock in a transaction on Friday, June 6th. The shares were sold at an average price of $112.05, for a total transaction of $10,954,792.35. Following the completion of the transaction, the director directly owned 75,000 shares of the company's stock, valued at approximately $8,403,750. The trade was a 56.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 291,744 shares of company stock worth $32,705,007 in the last quarter. Insiders own 1.50% of the company's stock.
HealthEquity Profile
(
Free Report)
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Featured Articles

Before you consider HealthEquity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HealthEquity wasn't on the list.
While HealthEquity currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.